Ligand Pharmaceuticals Secures Class Action Dismissal

Successfully defended Ligand Pharmaceuticals, Inc. and its subsidiary in a class action related to the sale of Neurogen to Ligand and co-defendant Neon Signal. Plaintiffs voluntarily dismissed the action without any payment to plaintiff or his attorneys, allowing the sale to proceed as scheduled (Guzman v. Neurogen, Ligand, et al).